Literature DB >> 26243982

Secondary haemochromatosis in a haemodialysis patient.

Lu Cheng1, Xi Tang1, Ping Fu1, Fang Liu1.   

Abstract

A 39-year-old woman with end-stage renal disease, which was maintained on haemodialysis, developed secondary haemochromatosis after receiving blood transfusions and intravenous iron supplementation without sufficient serum ferritin concentration monitoring. The patient received intravenous deferoxamine three times a week, combined with high-dose recombinant human erythropoietin therapy and haemodialysis. After three months, improvements in biochemical indicators and iron overload were noted.

Entities:  

Keywords:  ESRD; HFE gene; deferoxamine; haemodialysis; secondary haemochromatosis

Mesh：

Substances：

Year:  2015        PMID： 26243982      PMCID： PMC4520925          DOI： 10.11622/smedj.2015116

Source DB:  PubMed          Journal:  Singapore Med J        ISSN： 0037-5675            Impact factor:   1.858


  14 in total

Review 1.  Disorders of iron metabolism.

Authors:  N C Andrews
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

Review 2.  EASL International Consensus Conference on Haemochromatosis.

Authors:  P Adams; P Brissot; L W Powell
Journal:  J Hepatol       Date:  2000-09       Impact factor: 25.083

3.  Continuous subcutaenous administration of deferoxamine in patients with iron overload.

Authors:  R D Propper; B Cooper; R R Rufo; A W Nienhuis; W F Anderson; H F Bunn; A Rosenthal; D G Nathan
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

Review 4.  Objectives and mechanism of iron chelation therapy.

Authors:  Chaim Hershko; Gabriela Link; Abraham M Konijn; Z Ioav Cabantchik
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

5.  Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis.

Authors:  Michaela C Brown; Dairena Gaffney; Clare Gemmell; Eleanor Oakes; Scott Morris; Richard Spooner; Alan G Jardine; Colin C Geddes
Journal:  Hemodial Int       Date:  2009-08-28       Impact factor: 1.812

Review 6.  Recognition and management of hereditary hemochromatosis.

Authors:  David J Brandhagen; Virgil F Fairbanks; William Baldus
Journal:  Am Fam Physician       Date:  2002-03-01       Impact factor: 3.292

7.  MR imaging findings of iron overload.

Authors:  Marcony Queiroz-Andrade; Roberto Blasbalg; Cinthia D Ortega; Marco A M Rodstein; Ronaldo H Baroni; Manoel S Rocha; Giovanni G Cerri
Journal:  Radiographics       Date:  2009-10       Impact factor: 5.333

8.  Hemosiderosis secondary to chronic parenteral iron therapy in maintenance hemodialysis patients.

Authors:  T O Pitts; G L Barbour
Journal:  Nephron       Date:  1978       Impact factor: 2.847

Review 9.  Iron chelation therapy in the management of thalassemia: the Asian perspectives.

Authors:  Vip Viprakasit; Chan Lee-Lee; Quah Thuan Chong; Kai-Hsin Lin; Archrob Khuhapinant
Journal:  Int J Hematol       Date:  2009-10-29       Impact factor: 2.490

Review 10.  The treatment of secondary hemochromatosis.

Authors:  Norbert Gattermann
Journal:  Dtsch Arztebl Int       Date:  2009-07-24       Impact factor: 5.594
View more
  1 in total

Review 1.  Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.

Authors:  Joshua M Kaplan; Neeraj Sharma; Sean Dikdan
Journal:  Int J Mol Sci       Date:  2018-01-29       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.